LRB 139

Drug Profile

LRB 139

Latest Information Update: 03 Mar 2008

Price : $50

At a glance

  • Originator Istituto Lusofarmaco
  • Class Antihypertensives
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 03 Mar 2008 Discontinued - Preclinical for Hypertension in Italy (unspecified route)
  • 16 Dec 1999 No-Development-Reported for Hypertension in Italy (Unknown route)
  • 26 May 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top